AngioDynamics reports Q2 adjusted EPS 0c, consensus (10c)

Reports Q2 revenue $79.4M, consensus $76.43M. “We delivered an excellent second quarter, with continued strong Med Tech growth driving our overall performance,” commented Jim Clemmer, President and Chief Executive Officer of AngioDynamics (ANGO), Inc. “Across our Med Tech portfolio, we’re seeing the benefits of our strategic transformation as our innovative platform technologies, from Auryon to Mechanical Thrombectomy to NanoKnife, continue taking share in large, attractive markets. The momentum across our technology platforms demonstrates the strength of our diversified Med Tech portfolio. We will continue to invest in the long-term growth of our Med Tech portfolio. During the quarter, we advanced several important initiatives, including securing FDA approval on the IDE for right-sided endocarditis and the AlphaVac line extension. In addition, we received FDA IDE approval for our AlphaVac blood return study, an important milestone as we expand our portfolio of best-in-class solutions for physicians treating acute pulmonary embolism.”